1 active not recruiting, 1 completed, 1 terminated. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow Focal Segmental Glomerulosclerosis: new trials by email Literature Review of Focal Segmental Glomerulosclerosis trials Research Report on Focal Segmental Glomerulosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Sparsentan - Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Active not recruiting | Travere Therapeutics, Inc. | 20 | 2025-10-07 | 2026-06-23 |
| Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Dapagliflozin - Focal Segmental Glomerulosclerosis | Phase 4 | Completed | University Health Network, Toronto | 10 | 2015-09-01 | 2018-01-16 |
| Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Aliskiren, Valsartan - Proteinuric Kidney Disease, Diabetic Nephropathy | Phase 4 | Terminated | Columbia University | 46 | 2009-09-01 | 2014-05-15 |
Glomerulosclerosis, Focal Segmental (3) · Proteinuria (2) · Diabetic Nephropathies (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranous (1) · Kidney Diseases (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Glomerulonephritis (3) · Male Urogenital Diseases (3) · Nephritis (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Kidney Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Urination Disorders (2) · Urological Manifestations (2) · Autoimmune Diseases (1) · Chronic Disease (1) · Diabetes Complications (1)
Valsartan (1) · aliskiren (1) · dapagliflozin (1) · sparsentan (1)
Columbia University (1) · Travere Therapeutics, Inc. (1) · University Health Network, Toronto (1)
United States (2) · Canada (1)
Pietro Canetta, MD (1) · Radko Komers, MD, PhD (1)